ArticleClinical epigenetics2018
Dynamics of
Open access · goldAbstract read
In one paragraph
Article in Clinical epigenetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2022Pooled it
- Emerging trends in bone marrow organoid research: From hematopoietic microenvironment reconstruction to translational and regenerative theranostic applications.Theranostics · 2026Review
- [Dynamic changes in genetic mutations in myelodysplastic neoplasms with progressive disease and leukemic transformation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- The Role of the DNA Methyltransferase Family and the Therapeutic Potential of DNMT Inhibitors in Tumor Treatment.Current oncology (Toronto, Ont.) · 2025Review
- Hotspot gene mutations and treatment response in myelodysplastic syndromes (MDS): predictive biomarkers and targeted strategies.Frontiers in medicine · 2025Review
- Crosstalk between DNA methylation and hypoxia in acute myeloid leukaemia.Clinical epigenetics · 2023Review
- Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by XPO1 inhibitors.British journal of haematology · 2023Article
- Usefulness of New Neutrophil-Related Hematologic Parameters in Patients with Myelodysplastic Syndrome.Cancers · 2023Article
- P53 IHC Result as a Prognostic Tool in MDS.Iranian journal of pathology · 2023Article
- Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment.Cancers · 2022Review
- The methyltransferase domain of DNMT1 is an essential domain in acute myeloid leukemia independent of DNMT3A mutation.Communications biology · 2022Article
- [Risk factors for leukemia transformation in patients with myelodysplastic syndromes].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms.Cancer research communications · 2022Article
- Predictive values of mutational variant allele frequency in overall survival and leukemic progression of myelodysplastic syndromes.Journal of cancer research and clinical oncology · 2022Article
- The spectrum of genetic mutations in myelodysplastic syndrome: Should we update prognostication?EJHaem · 2022Review
- Article
- Activation ofCancer research · 2021Article
- Article
- Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies.Journal of biomedical science · 2020Review
- Age-AssociatedInternational journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Ming-En Lin1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No.7, Chung Shan S. Rd., Zhongzheng Dist, Taipei, 10002 Taiwan.
Hsin-An Hou1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No.7, Chung Shan S. Rd., Zhongzheng Dist, Taipei, 10002 Taiwan.
Cheng-Hong Tsai4Tai-Cheng Stem Cell Therapy Center, National Taiwan University, Taipei, Taiwan.
Shang-Ju Wu1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No.7, Chung Shan S. Rd., Zhongzheng Dist, Taipei, 10002 Taiwan.
Yuan-Yeh Kuo5Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Mei-Hsuan Tseng1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No.7, Chung Shan S. Rd., Zhongzheng Dist, Taipei, 10002 Taiwan.
Ming-Chih Liu6Departments of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
Chia-Wen Liu6Departments of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
Wen-Chien Chou1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No.7, Chung Shan S. Rd., Zhongzheng Dist, Taipei, 10002 Taiwan.
Chien-Yuan Chen1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No.7, Chung Shan S. Rd., Zhongzheng Dist, Taipei, 10002 Taiwan.
Jih-Luh Tang1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No.7, Chung Shan S. Rd., Zhongzheng Dist, Taipei, 10002 Taiwan.
Ming Yao1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No.7, Chung Shan S. Rd., Zhongzheng Dist, Taipei, 10002 Taiwan.
Chi-Cheng Li1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No.7, Chung Shan S. Rd., Zhongzheng Dist, Taipei, 10002 Taiwan.
Shang-Yi Huang1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No.7, Chung Shan S. Rd., Zhongzheng Dist, Taipei, 10002 Taiwan.
Bor-Sheng Ko1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No.7, Chung Shan S. Rd., Zhongzheng Dist, Taipei, 10002 Taiwan.
Szu-Chun Hsu7Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Chien-Ting Lin1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No.7, Chung Shan S. Rd., Zhongzheng Dist, Taipei, 10002 Taiwan.
Hwei-Fang Tien1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, No.7, Chung Shan S. Rd., Zhongzheng Dist, Taipei, 10002 Taiwan.
National Taiwan University Hospital · TWNational Taiwan University · TW
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Results: In this study, Conclusions:
Indexed as
MutationAdolescentAdultAgedAged, 80 and overDisease ProgressionDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AHumansMaleMiddle AgedMyelodysplastic SyndromesPrognosisSequence Analysis, DNASurvival AnalysisYoung AdultDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanDNMT3AMyelodysplastic syndromePaired samplesPrognosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.